Combined metabolomic and proteomic analysis of sepsis related acute liver injury and its pathogenesis research
Copyright © 2024 Elsevier B.V. All rights reserved..
BACKGROUND: Sepsis-induced acute liver injury is common in patients in intensive care units. However, the exact mechanism of this condition remains unclear. The purpose of this study was to investigate the roles and mechanisms of proteins and metabolites in the liver tissue of mice after sepsis and elucidate the molecular biological mechanisms of sepsis-related liver injury.
METHODS: First, a lipopolysaccharide (LPS)-induced sepsis mouse model was established. Then, according to alanine aminotransferase (ALT) and aspartate aminotransferase (AST) detection in mouse serum and liver histopathological examination (HE) staining, the septic mice were divided into two groups: acute liver injury after sepsis and nonacute liver injury after sepsis. Metabolomics and proteomic analyses were performed on the liver tissues of the two groups of mice to identify significantly different metabolites and proteins. The metabolomics and proteomics results were further analysed to identify the biological indicators and pathogenesis related to the occurrence and development of sepsis-related acute liver injury at the protein and metabolite levels.
RESULTS: A total of 14 differentially expressed proteins and 46 differentially expressed metabolites were identified. Recombinant Erythrocyte Membrane Protein Band 4.2 (Epb42) and adenosine diphosphate (ADP) may be the key proteins and metabolites responsible for sepsis-related acute liver injury, according to the correlation analysis of proteomics and metabolomics. The expression of the differential protein Epb42 was further verified by western blot (WB) detection.
CONCLUSIONS: Our study suggests that the differential protein Epb42 may be key proteins causing sepsis-associated acute liver injury, providing new and valuable information on the possible mechanism of sepsis-associated acute liver injury.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
---|---|
Enthalten in: |
International immunopharmacology - 130(2024) vom: 30. März, Seite 111666 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhang, Jin [VerfasserIn] |
---|
Links: |
---|
Themen: |
Bioinformatics |
---|
Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.intimp.2024.111666 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369026047 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369026047 | ||
003 | DE-627 | ||
005 | 20240325234959.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240229s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.intimp.2024.111666 |2 doi | |
028 | 5 | 2 | |a pubmed24n1346.xml |
035 | |a (DE-627)NLM369026047 | ||
035 | |a (NLM)38412671 | ||
035 | |a (PII)S1567-5769(24)00184-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhang, Jin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Combined metabolomic and proteomic analysis of sepsis related acute liver injury and its pathogenesis research |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.03.2024 | ||
500 | |a Date Revised 25.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
520 | |a BACKGROUND: Sepsis-induced acute liver injury is common in patients in intensive care units. However, the exact mechanism of this condition remains unclear. The purpose of this study was to investigate the roles and mechanisms of proteins and metabolites in the liver tissue of mice after sepsis and elucidate the molecular biological mechanisms of sepsis-related liver injury | ||
520 | |a METHODS: First, a lipopolysaccharide (LPS)-induced sepsis mouse model was established. Then, according to alanine aminotransferase (ALT) and aspartate aminotransferase (AST) detection in mouse serum and liver histopathological examination (HE) staining, the septic mice were divided into two groups: acute liver injury after sepsis and nonacute liver injury after sepsis. Metabolomics and proteomic analyses were performed on the liver tissues of the two groups of mice to identify significantly different metabolites and proteins. The metabolomics and proteomics results were further analysed to identify the biological indicators and pathogenesis related to the occurrence and development of sepsis-related acute liver injury at the protein and metabolite levels | ||
520 | |a RESULTS: A total of 14 differentially expressed proteins and 46 differentially expressed metabolites were identified. Recombinant Erythrocyte Membrane Protein Band 4.2 (Epb42) and adenosine diphosphate (ADP) may be the key proteins and metabolites responsible for sepsis-related acute liver injury, according to the correlation analysis of proteomics and metabolomics. The expression of the differential protein Epb42 was further verified by western blot (WB) detection | ||
520 | |a CONCLUSIONS: Our study suggests that the differential protein Epb42 may be key proteins causing sepsis-associated acute liver injury, providing new and valuable information on the possible mechanism of sepsis-associated acute liver injury | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Bioinformatics | |
650 | 4 | |a Metabonomics | |
650 | 4 | |a Pathogenesis | |
650 | 4 | |a Proteomics | |
650 | 4 | |a Sepsis-related acute liver injury | |
650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
700 | 1 | |a Wang, Xibo |e verfasserin |4 aut | |
700 | 1 | |a Peng, Yahui |e verfasserin |4 aut | |
700 | 1 | |a Wei, Jieling |e verfasserin |4 aut | |
700 | 1 | |a Luo, Yinghao |e verfasserin |4 aut | |
700 | 1 | |a Luan, Feiyu |e verfasserin |4 aut | |
700 | 1 | |a Li, Hongxu |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Yang |e verfasserin |4 aut | |
700 | 1 | |a Wang, Changsong |e verfasserin |4 aut | |
700 | 1 | |a Yu, Kaijiang |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 130(2024) vom: 30. März, Seite 111666 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
773 | 1 | 8 | |g volume:130 |g year:2024 |g day:30 |g month:03 |g pages:111666 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2024.111666 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 130 |j 2024 |b 30 |c 03 |h 111666 |